Stifel Reiterates Buy Rating on Celldex Therapeutics (CLDX) After Q3 Update
Tweet Send to a Friend
Stifel analyst Alex Thompson reiterated a Buy rating and $58.00 price target on Celldex Therapeutics (NASDAQ: CLDX).The analyst commented, "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
